<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>318</serviceExecutionTime><Drug id="80404"><DrugName>epoetin alfa follow-on biologics, LG Life Sciences</DrugName><DrugNamesKey><Name id="42989028">Espogen</Name><Name id="42758552">epoetin alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>epoetin alfa</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>epoetin alfa follow-on biologics, LG Life Sciences</Value></Name><Name><Value>Espogen</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>repurposed epoetin alfa (cerebral palsy), LG Life Sciences</Value></Name></DrugSynonyms><CompanyOriginator id="30057">LG Life Sciences Ltd</CompanyOriginator><CompaniesPrimary><Company id="30057">LG Life Sciences Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="80404" type="Drug"><TargetEntity id="126092" type="siDrug">Epoetin</TargetEntity></SourceEntity><SourceEntity id="30057" type="Company"><TargetEntity id="4295882492" type="organizationId">LG Life Sciences Ltd</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"/><TargetEntity id="D000740" type="MeSH"/><TargetEntity id="-201701473" type="omicsDisease"/><TargetEntity id="988" type="siCondition"/></SourceEntity><SourceEntity id="2620" type="ciIndication"><TargetEntity id="G80" type="ICD10"/><TargetEntity id="10008129" type="MEDDRA"/><TargetEntity id="D002547" type="MeSH"/><TargetEntity id="-967985093" type="omicsDisease"/><TargetEntity id="163" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-03045" type="ciTarget"><TargetEntity id="92553377420563" type="siTarget">Erythropoietin</TargetEntity><TargetEntity id="245" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anemia - South Korea - Aug-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="17">Anemia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="2620">Cerebral palsy</Indication></IndicationsSecondary><ActionsPrimary><Action id="12162">Erythropoietin ligand</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="74">Glycoprotein</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology><Technology id="961">Follow on biological product</Technology></Technologies><LastModificationDate>2018-07-27T11:29:31.000Z</LastModificationDate><ChangeDateLast>2018-07-27T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-23T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences&lt;/ulink&gt; has developed and launched Espogen (presumed to be BEPO-A), a follow-on biologic version of &lt;ulink linkID="6797" linkType="Drug"&gt;epoetin alfa&lt;/ulink&gt; as sc or iv formulation, for the treatment of anemia in patients with chronic renal failure (CRF). In April 1998, the drug was launched in South Korea [&lt;ulink linkID="1317428" linkType="Reference"&gt;1317428&lt;/ulink&gt;], [&lt;ulink linkID="1653472" linkType="Reference"&gt;1653472&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The company was also developing the drug as a repurposed formulation for the potential treatment cerebral palsy. In June 2012, a phase I 	trial was initiated in Korea in children with  cerebral palsy. The trial was expected to complete in June 2013 [&lt;ulink linkID="1439471" linkType="Reference"&gt;1439471&lt;/ulink&gt;]. In November 2012, Espogen was listed as being in preclinical development in countries outside of South Korea for the potential  treatment of anemia in patients with CRF [&lt;ulink linkID="1346383" linkType="Reference"&gt;1346383&lt;/ulink&gt;]. However, no development has been reported for some time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2015, a randomized, crossover assigned, bio-equivalence, phase I trial (NCT02426151; LG-EPCL009) was initiated in healthy subjects (expected n =  48) to compare pharmacokinetic and pharmacodynamic profiles of Espogen and REPO-A. The trial was expected to be completed in August 2015 [&lt;ulink linkID="1655303" linkType="Reference"&gt;1655303&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, an open-label, safety/efficacy phase I 	trial (&lt;ulink linkID="117149" linkType="Protocol"&gt;NCT01586052&lt;/ulink&gt;; CPEPOPhase1) was initiated in Korea in children (n = 10) with  cerebral palsy. The trial was expected to complete in June 2013 [&lt;ulink linkID="1439471" linkType="Reference"&gt;1439471&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2012-08-23T00:00:00.000Z</StatusDate><Source id="1317428" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="WO">World</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2015-12-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2620">Cerebral palsy</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="WO">World</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2012-12-03T00:00:00.000Z</StatusDate><Source id="1346383" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30057">LG Life Sciences Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2620">Cerebral palsy</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1439471" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03045"><Name>Erythropoietin ligand</Name><SwissprotNumbers><Swissprot>P01588</Swissprot><Swissprot>P07321</Swissprot><Swissprot>P07865</Swissprot><Swissprot>P29676</Swissprot><Swissprot>P33707</Swissprot><Swissprot>P33708</Swissprot><Swissprot>P33709</Swissprot><Swissprot>P48617</Swissprot><Swissprot>P49157</Swissprot><Swissprot>Q28513</Swissprot><Swissprot>Q867B1</Swissprot><Swissprot>Q9GKA2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ANALIZA Inc" id="1004873"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chung Shan Medical University" id="1031584"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Raygene Biotech International Inc" id="1138425"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novo Nordisk A/S" id="18614"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Of Massachusetts" id="20615"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Louisville" id="21246"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Deutsches Krebsforschungszentrum" id="23844"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neose Technologies Inc" id="24203"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>